Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD)
Phase 2
Completed
- Conditions
- Depressive Disorder, Major
- Registration Number
- NCT00413023
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
The purpose of this study is to assess the efficacy, safety and tolerability of GW679769 patients with Major depressive Disorder (MDD).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 348
Inclusion Criteria
Not provided
Read More
Exclusion Criteria
- Primary diagnosis within the past 6 months of another Axis 1 disorder such as an anxiety disorder.
- Use of medications for a psychiatric condition including herbals in the past 2-12 weeks according to medication type.
- Subjects who, in the investigator's judgement, pose a current, serious suicidal or homicidal risk or have made a suicide attempt within the past 6 months.
- Subjects who currently meet or who met within 6 months prior to screening DSM-IV criteria for substance abuse or subjects who currently meet or who met within 6 months prior to screening DSM-IV criteria for substance dependence (other than nicotine).
- Significantly abnormal blood or urine laboratory tests or electrocardiogram (ECG).
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change in score on a Depression rating scale following 8 weeks of treatment.
- Secondary Outcome Measures
Name Time Method Change in score on a number of rating scales following 8 weeks of treatment assessing symptomatic, behavioural and functional parameters which together provide a more complete description of the disorder.
Trial Locations
- Locations (1)
GSK Investigational Site
🇸🇪Solna, Sweden